American Optometric Society seeks permanent injunction

Article

In an effort to convince optometrists to become board certified, the American Board of Optometry has engaged in deceptive and false advertising and unfair competition, according to a lawsuit filed by the AOS against the ABO.

The suit, filed in the U.S. District Court for the Central District of California, arose from statements the ABO made on it its Web site, http://www.americanboardofoptometry.org/, including use of the ABOVE acronym, which stands for American Board of Optometry Verification of Excellence. Specifically the ABO stated that ABO-certified doctors:

"This misleads the public because it implies training and knowledge that a 'merely licensed' optometrist does not have. So, the fact that the 'ABOVE' message is gone does nothing to mitigate the basis for the lawsuit," added Craig S. Steinberg, OD, JD, general counsel for the AOS who filed the suit.

For these reasons, the AOS is seeking an injunction to permanently cease and desist this type of advertising.

The ABO has discontinued use of the ABOVE acronym, but the AOS remains concerned about the use of similar messages in the future. "Just because it is currently changed or removed from the ABO site does not mean it cannot be placed back on unless there is a permanent injunction," Dr. Miller said.

In fact, the suit states that the AOS' membership will suffer competitive harm, as a result of ABO advertising. At the same time, by making ABO certification a necessity to remain competitive, the ABO will increase the sales of its own products and services, the suit charges.

ABO Chairman David Cockrell, OD, declined to comment on the specifics of the pending litigation. He did, however, deny the allegations against the ABO and stated that the ABO plans to "vigorously defend its position."

Recent Videos
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Dr Paul Karpecki discusses atropine formulation from Sydnexis following NDA acceptance by FDA
Ali Tafreshi sits down with Optometry Times to discuss Topcon's "Healthcare from the Eye" initiative.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
OptiLIFT in action: Dr. Julie McLaughlin's experience with the new device
© 2025 MJH Life Sciences

All rights reserved.